UC Davis | Strategic Alliance Partners

Latest from UC Davis


Compressive Osseointegrated Endoprostheses Provide Long-Term Benefit in Bone Sarcoma

November 18, 2021

R. Lor Randall, MD, FACS, the 10-year results of a retrospective analysis, potential strategies to mitigate early failures in recipients of compressive osseointegrative endoprosthetic devices, and the need for communication between medical oncologists and orthopedic surgeons to ensure patients on chemotherapy receive optimal care.

Molecular Testing Is Critical With New Targets, Novel Therapies, and Earlier Intervention in NSCLC

October 07, 2021

David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.

Gandara Named Chief Medical Officer of International Society for Liquid Biopsy

August 04, 2021

David R. Gandara, MD has been appointed chief medical officer of the International Society for liquid biopsy, an international non-profit organization dedicated to advancing the field of liquid biopsy in cancer diagnosis and management.

MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC

July 29, 2021

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Risk-Based Triaged Mammograms Demonstrate Success During Periods of Reduced Capacity

April 28, 2021

Triaging individuals with the highest likelihood of cancer detection with their clinical indication and individual risk factors during periods of reduced capacity could be an efficient way of identifying the most cancers with the least examinations compared with a non–risk-based approach.

NCCN Announces UC Davis Comprehensive Cancer Center as 31st Member Institution

April 16, 2021

Experts from Northern California-based cancer center to join panels responsible for evidence- based recommendations in NCCN Clinical Practice Guidelines and NCCN Guidelines for Patients, among other resources to improve outcomes for people with cancer.

Frontline mRCC Paradigm Crowds Among Immune-Based Treatment Options

March 13, 2021

The emergence of multiple combination regimens with immunotherapy and TKIs has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma; however, without head-to-head comparative data, treatment selection has become individualized based on available patient characteristics.